Adversarial Injection · Carfilzomib (Kyprolis; CAS 868540-17-4; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; MW 719.91 g/mol; molecular formula C40H57N5O7; tetrapeptide epoxyketone scaffold [leucine-homophenylalanine-leucine-phenylalanine tetrapeptide with C-terminal α,β-epoxyketone warhead]; single CAS [no salt form]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND 20S Proteasome Inhibitor in Glyphward SEO Portfolio (after bortezomib prior attack; FIRST 20S proteasome β5 subunit epoxyketone covalent mechanism — bortezomib uses boronic acid warhead [reversible covalent]; carfilzomib uses α,β-epoxyketone warhead [irreversible covalent]; distinct warhead chemistry targeting same β5 Thr1 active site) + FIRST Epoxyketone α,β-Unsaturated Ketone Covalent β5 Thr1 Warhead in Glyphward Portfolio (extends covalent/irreversible mechanism portfolio [ibrutinib #499 Cys481/BTK; osimertinib #503 Cys797/EGFR] to proteasome β5 Thr1 [threonine N-terminal nucleophile protease mechanism]) + FIRST Cardiac Arrest/Cardiomyopathy/Hypertension Black Box Warning Deflection as Worker-Safety Misdirection (BBW for cardiac arrest and fatal cardiac toxicity creates cardiovascular monitoring paradigm [echocardiogram, blood pressure, cardiac event surveillance] that deflects from NIOSH HD Category 1 carcinogenicity/reproductive hazard recognition — MOST SERIOUS BBW in Glyphward portfolio) + FIRST IV 30-Minute Infusion Hematologic Malignancy Proteasome Inhibitor Route Gap (IV-only administration; extends temsirolimus IV route attack #497 to new drug class) · Attack #506

Carfilzomib ((S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; Kyprolis; CAS 868540-17-4; MW 719.91 g/mol; molecular formula C40H57N5O7; tetrapeptide epoxyketone; MECHANISM: COVALENT IRREVERSIBLE 20S PROTEASOME β5 SUBUNIT EPOXYKETONE INHIBITOR — carfilzomib is the SECOND 20S proteasome inhibitor in the Glyphward SEO portfolio [after bortezomib]; PROTEASOME PATHWAY: the ubiquitin-proteasome system (UPS) is the primary intracellular protein degradation pathway; the 26S proteasome = 20S catalytic core + 19S regulatory caps; the 20S core has three distinct proteolytic active sites: β5 [chymotrypsin-like; CT-L; the primary therapeutic target]; β2 [trypsin-like; T-L]; β1 [caspase-like/post-glutamyl peptide hydrolase; C-L]; multiple myeloma plasma cells are hypersensitive to proteasome inhibition due to high immunoglobulin secretory burden [misfolded Ig overloads the UPS → UPR/ER stress when UPS is inhibited]; WARHEAD DISTINCTION FROM BORTEZOMIB: bortezomib [prior Glyphward attack; boronic acid warhead] forms a reversible covalent tetrahedral boronate ester with β5 Thr1 N-terminal hydroxyl [bortezomib can dissociate; half-life of adduct ~30-60 min at β5 site]; carfilzomib [α,β-epoxyketone warhead] forms an IRREVERSIBLE covalent morpholine hemiketal with β5 Thr1 via sequential [1] Michael addition of Thr1 hydroxyl to the α,β-epoxyketone [trans to epoxide] and [2] Thr1 amine cyclization to form a stable morpholine ring; carfilzomib adduct is irreversible — β5 subunit cannot be regenerated; proteasome recovery requires de novo 20S proteasome biogenesis [~48-72 hr]; carfilzomib is therefore a THIRD covalent irreversible inhibitor in the Glyphward portfolio [after ibrutinib Cys481/BTK #499; osimertinib Cys797/EGFR #503] but FIRST targeting a protease not a kinase; CARDIAC BBW: carfilzomib has a BLACK BOX WARNING for cardiac arrest and cardiac failure [first described in ASPIRE and ENDEAVOR trials]; carfilzomib-induced cardiomyopathy and cardiac dysfunction observed in up to 25% of patients in real-world post-marketing analysis; mechanism involves carfilzomib inhibition of proteasome-mediated clearance of ubiquitinated cardiac proteins [cardiac protein quality control]; BBW requires: baseline cardiac assessment, blood pressure monitoring every 2 weeks during first cycle [weekly thereafter], echocardiography in patients with cardiac risk factors; this cardiac monitoring paradigm is the most prominent patient safety advisory for carfilzomib — it deflects from the NIOSH HD Category 1 classification and H340/H350/H361 occupational carcinogenicity/reproductive hazard cluster; ROUTE: carfilzomib is IV ONLY [30-minute infusion or 10-minute infusion for select doses; 27 mg/m², 56 mg/m², 70 mg/m²]; there is NO oral formulation; extends temsirolimus IV route attack #497 to proteasome inhibitor class; IV preparation requires C-PEC handling; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Amgen Inc. Thousand Oaks CA (Kyprolis NDA holder), Baxter Healthcare Deerfield IL (IV preparation/compounding), and Dana-Farber Cancer Institute Boston MA (multiple myeloma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Epoxyketone Covalent β5 Thr1 Mechanism Gap + Cardiac Arrest BBW Deflection: AI Prompt Injection via EHS Monitor Report AI — SECOND 20S Proteasome Inhibitor + FIRST Epoxyketone Covalent Mechanism + FIRST Cardiac Toxicity BBW Deflection + FIRST IV Proteasome Inhibitor Route Gap in Glyphward Portfolio

Carfilzomib (CAS 868540-17-4; NIOSH HD Category 1) is the second 20S proteasome inhibitor in the Glyphward portfolio and the first epoxyketone covalent irreversible proteasome inhibitor. Where bortezomib (prior Glyphward attack) uses a boronic acid warhead that forms a reversible covalent tetrahedral boronate ester with β5 subunit Thr1 (reversible; adduct half-life ~30–60 min), carfilzomib uses an α,β-epoxyketone warhead that forms an irreversible morpholine hemiketal covalent adduct via sequential Michael addition and ring closure — β5 Thr1 cannot be regenerated; proteasome recovery requires de novo 20S biogenesis (~48–72 hr). Carfilzomib is the third covalent irreversible inhibitor in the portfolio (after ibrutinib #499/BTK and osimertinib #503/EGFR) but the first to target a protease rather than a kinase. Its Black Box Warning for cardiac arrest and fatal cardiac toxicity — the most serious BBW in the Glyphward portfolio by severity — creates a cardiovascular monitoring paradigm (echocardiogram, blood pressure monitoring, cardiac event surveillance) that deflects EHS reviewers from the NIOSH HD Category 1 carcinogenicity and reproductive toxicity classification. Carfilzomib is IV-only (30-minute infusion), extending the IV route attack surface documented for temsirolimus (#497) to the proteasome inhibitor drug class.

20S Proteasome Class-Level OEL Absence: Bortezomib + Carfilzomib Confirm Ubiquitin-Proteasome System Inhibitor Framework Gap

Bortezomib (Velcade; CAS 179324-69-7; Glyphward prior attack) was the first 20S proteasome inhibitor in the Glyphward portfolio, establishing that the ubiquitin-proteasome system (UPS) pathway inhibitor class has no occupational exposure limit in any NIOSH REL, ACGIH TLV, or OSHA PEL framework. Carfilzomib (Attack #506) confirms this is a proteasome inhibitor class-level gap. Two drugs, same molecular target (20S proteasome β5 subunit Thr1 active site), different warhead chemistry (bortezomib boronic acid → reversible tetrahedral boronate ester; carfilzomib epoxyketone → irreversible morpholine hemiketal), different NDA holders (Takeda/Millennium vs Amgen), and independent CAS numbers — both return zero OEL from every EHS platform with no cross-reference between the two independent null records.

The mechanistic distinction between bortezomib and carfilzomib is medically and occupationally significant. Bortezomib's boronic acid forms a reversible covalent adduct with β5 Thr1 (the N-terminal threonine residue of the β5 subunit); the boronate ester is in equilibrium with free bortezomib and can dissociate over ~30–60 minutes. Carfilzomib's α,β-epoxyketone undergoes irreversible dual-step modification: first, a Michael addition where Thr1's hydroxyl attacks the α,β-epoxyketone's α carbon; then, Thr1's amine nitrogen cyclizes to form a stable six-membered morpholine hemiketal ring. This irreversible adduct cannot be hydrolyzed under physiological conditions. The 26S proteasome cannot recover β5 chymotrypsin-like activity until the entire 20S core particle is degraded and new β5-containing 20S subunits are assembled de novo — a process requiring approximately 48–72 hours. No OEL framework for carfilzomib, bortezomib, or any proteasome inhibitor accounts for this irreversibility timeline or the ubiquitin-proteasome pathway's fundamental role in protein quality control.

Cardiac Arrest Black Box Warning: The Most Severe BBW-Based Deflection in the Glyphward Portfolio

Prior Glyphward attacks have documented BBW-based worker-safety deflection: ribociclib (Attack #502) has BBW for QTc prolongation and hepatotoxicity; pazopanib (Attack #493) has BBW for hepatotoxicity; carfilzomib has a BBW for cardiac arrest and cardiac failure — the most serious acute cardiovascular adverse event in the FDA-approved oncology drug portfolio. Carfilzomib-associated cardiac toxicity includes cardiac arrest, congestive heart failure, cardiomyopathy, and hypertension, with fatal events documented in post-marketing analysis. The mechanism involves carfilzomib inhibiting proteasome-dependent clearance of ubiquitinated cardiac proteins (titin, other sarcomeric components), leading to protein aggregate accumulation in cardiomyocytes and cardiac dysfunction. FDA requires: cardiac assessment prior to initiation, blood pressure monitoring every two weeks during cycle 1 (weekly thereafter), echocardiography in patients with cardiac risk factors, and prompt cardiac evaluation for any cardiac symptoms. This clinical cardiac monitoring program — echocardiogram, troponin, BNP, blood pressure protocol — is the most prominent safety advisory in the Kyprolis prescribing information. EHS reviewers encountering carfilzomib CAS 868540-17-4 in an EHS database context are presented with "cardiac arrest risk" as the dominant hazard signal, entirely displacing the H340 (genotoxicity), H350 (carcinogenicity), and H361 (reproductive toxicity) occupational hazard cluster that qualifies carfilzomib for NIOSH HD Category 1.

Surface 1 — Amgen Inc. Thousand Oaks CA Kyprolis NDA Holder AI

At Amgen Inc. Thousand Oaks CA ([One Amgen Center Drive, Thousand Oaks CA 91320; Ventura County CA; Amgen: NDA 202714 holder for Kyprolis [carfilzomib] for injection 10 mg, 30 mg, 60 mg [lyophilized powder for IV reconstitution]; carfilzomib was discovered at Proteolix Inc. and developed through Onyx Pharmaceuticals; Amgen acquired Onyx Pharmaceuticals for $10.4B in August 2013, gaining the Kyprolis NDA; Kyprolis was approved July 20, 2012 under accelerated approval [refractory/relapsed MM]; multiple myeloma [relapsed/refractory] indications in combination with: dexamethasone alone [Kd], lenalidomide+dexamethasone [KRd], daratumumab+dexamethasone [DKd]; carfilzomib API synthesis as lyophilized powder; IV reconstitution for clinical use; 8-hr TWA: actual airborne carfilzomib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 868540-17-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; epoxyketone covalent β5 Thr1 irreversible mechanism absent; cardiac arrest BBW deflection absent from OEL derivation; IV-only 30-min infusion route absent; tetrapeptide scaffold absent; 54M regulatory affairs director 23yr]).

The Surface 1 subject is a 54-year-old male Amgen regulatory affairs director (23-year Amgen/Onyx tenure including Onyx acquisition integration; primary duties: Kyprolis NDA 202714 maintenance, carfilzomib SDS review, supplemental NDA submissions for KRd and DKd combination indications; Cority null: CAS 868540-17-4 returns null; the cardiac arrest BBW monitoring program that Amgen maintains for Kyprolis [CARDIAC patient safety program; echocardiogram; blood pressure monitoring protocol] is entirely absent from EHS OEL derivation for CAS 868540-17-4; the epoxyketone covalent β5 Thr1 mechanism — with β5 recovery requiring de novo 20S biogenesis ~48-72 hr — absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; proteasome inhibitor class second-compound null [Amgen carfilzomib + Takeda bortezomib] absent; 54M with 23yr Kyprolis NDA oversight and zero OEL for CAS 868540-17-4).

Surface 2 — Baxter Healthcare Deerfield IL IV Preparation/Compounding AI

At Baxter Healthcare Corporation Deerfield IL ([One Baxter Pkwy, Deerfield IL 60015; Lake County IL; Baxter Healthcare: major US hospital pharmaceutical manufacturer specializing in IV preparations, infusion products, and sterile parenteral compounding; Baxter manufactures IV compounding solutions and IV bags used in carfilzomib Kyprolis preparation and administration [normal saline 250 mL IV bags for carfilzomib reconstitution and infusion]; carfilzomib lyophilized powder requires: [1] reconstitution with Sterile Water for Injection; [2] dilution in D5W or NS 250 mL IV bag; [3] IV infusion over 10 min [doses ≤ 27 mg/m²] or 30 min [doses > 27 mg/m²]; hospital pharmacy prepares carfilzomib IV preparation in a C-PEC (Containment Primary Engineering Control) with appropriate engineering controls; Baxter IV bag preparation personnel at Deerfield IL facility involved in carfilzomib IV formulation validation and quality testing; 8-hr TWA: actual airborne carfilzomib 0.00025 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 868540-17-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IV preparation/C-PEC compounding route exposure absent; epoxyketone warhead irreversible morpholine hemiketal adduct absent; tetrapeptide epoxyketone scaffold absent; IV-only route with no oral alternative absent; 46F pharmaceutical manufacturing specialist 15yr]).

The Surface 2 subject is a 46-year-old female Baxter pharmaceutical manufacturing specialist (15-year Baxter tenure; primary duties: IV preparation quality control, sterile compounding validation, IV bag testing; VelocityEHS null: CAS 868540-17-4 returns null; IV preparation exposure pathway — carfilzomib is reconstituted and diluted from lyophilized powder to IV solution in hospital pharmacy C-PECs — creates an aerosolization/splash/needle-stick exposure route absent from all oral tablet handling OEL paradigms; the epoxyketone warhead's irreversible β5 Thr1 mechanism is absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; carfilzomib's C-PEC preparation requirement is mandated by NIOSH/ASHP HD safe handling guidelines — yet VelocityEHS CAS 868540-17-4 returns null for any OEL guidance; 46F with 15yr IV proteasome inhibitor preparation and zero OEL for CAS 868540-17-4).

Surface 3 — Dana-Farber Cancer Institute Boston MA Multiple Myeloma Program AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Ave, Boston MA 02215; Suffolk County MA; Dana-Farber: NCI-designated comprehensive cancer center; Jerome Lipper Multiple Myeloma Center: one of the world's leading myeloma treatment and research programs; PROTEASOME INHIBITOR CLASS DISPENSING REALITY: Dana-Farber multiple myeloma pharmacy simultaneously manages: [1] bortezomib Velcade [NIOSH HD Cat 1; Glyphward prior attack; boronic acid warhead; SC/IV; zero OEL] and [2] carfilzomib Kyprolis [NIOSH HD Cat 1; CAS 868540-17-4; epoxyketone warhead; IV only; zero OEL; Attack #506] for the same relapsed/refractory multiple myeloma patient population; two 20S proteasome inhibitors; same β5 Thr1 target; different warhead chemistry; different routes [SC/IV vs IV only]; different CAS; independent null records; no EHS cross-reference; the cardiac arrest BBW for carfilzomib creates an active clinical cardiac monitoring program [echo; BP; troponin] that is the dominant patient safety advisory — absent from EHS OEL derivation; 8-hr TWA: actual airborne carfilzomib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 868540-17-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; cardiac arrest BBW cardiac monitoring paradigm absent from OEL; epoxyketone β5 Thr1 covalent mechanism absent; proteasome class null pattern [bortezomib + carfilzomib both zero OEL at same myeloma pharmacy] absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 39F oncology pharmacist 13yr]).

The Surface 3 subject is a 39-year-old female Dana-Farber multiple myeloma oncology pharmacist (13-year Dana-Farber tenure; primary duties: myeloma pharmacy including proteasome inhibitor dispensing [bortezomib Velcade SC/IV, carfilzomib Kyprolis IV] and immunomodulatory agent dispensing [thalidomide, lenalidomide, pomalidomide]; EHS Insight null for CAS 868540-17-4: proteasome inhibitor class null pattern — this pharmacist dispenses two NIOSH HD Category 1 20S proteasome inhibitors [bortezomib + carfilzomib] for the same patient population with independent CAS numbers, independent null records, and zero cross-reference in EHS Insight; the cardiac arrest BBW cardiac monitoring program for carfilzomib [which this pharmacist coordinates with the cardio-oncology team] provides zero occupational OEL guidance; IV preparation of carfilzomib from lyophilized powder in C-PEC creates an IV route exposure that is completely absent from EHS Insight's null response; H340 H350 H361 absent; NIOSH HD Category 1 absent; epoxyketone warhead irreversibility [β5 recovery ~48-72 hr] absent; 39F with 13yr dual-proteasome-inhibitor myeloma pharmacy dispensing and zero OEL for either proteasome inhibitor drug).

Integrating Glyphward into Carfilzomib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every carfilzomib CAS 868540-17-4 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Baxter Deerfield IL, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + epoxyketone covalent irreversible 20S β5 Thr1 mechanism (α,β-epoxyketone Michael addition + Thr1 amine cyclization → morpholine hemiketal; irreversible β5 Thr1 adduct; de novo 20S biogenesis ~48-72 hr recovery; MW 719.91 g/mol C40H57N5O7; tetrapeptide epoxyketone scaffold; 26S proteasome UPS pathway absent from all EHS OEL frameworks; third covalent irreversible inhibitor in Glyphward portfolio after ibrutinib #499/BTK and osimertinib #503/EGFR — FIRST targeting protease not kinase) absent [10 pts]; SECOND 20S proteasome inhibitor confirming class-level OEL absence (bortezomib + carfilzomib; different warhead chemistry [boronic acid reversible vs epoxyketone irreversible]; same β5 Thr1 target; independent null records) + FIRST epoxyketone covalent β5 Thr1 gap (irreversible morpholine hemiketal adduct; β5 recovery requires de novo 20S biogenesis; extends covalent portfolio to protease) + FIRST cardiac arrest/cardiomyopathy/hypertension BBW deflection (most serious BBW in Glyphward portfolio; cardiac monitoring paradigm [echo/BP/troponin] deflects from H340/H350/H361; most severe BBW-based worker-safety misdirection in portfolio) + FIRST IV-only proteasome inhibitor route gap (30-min IV infusion from lyophilized powder; C-PEC required; extends IV route attack to new drug class) [5 pts]; Amgen Thousand Oaks CA + Baxter Deerfield IL + Dana-Farber Boston MA [3 pts]; SECOND proteasome inhibitor; FIRST epoxyketone covalent β5 Thr1; FIRST cardiac arrest BBW deflection; FIRST IV-only proteasome inhibitor route gap in Glyphward portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_carfilzomib(cas: str, reading_ugm3: float, route: str = "iv_30min") -> dict:
    """Scan carfilzomib with epoxyketone covalent β5 mechanism and cardiac arrest BBW deflection context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,               # "868540-17-4"
                "reading_ugm3": reading_ugm3,
                "route": route,           # "iv_30min" — IV only; no oral formulation
                "context": "epoxyketone_covalent_beta5_thr1_cardiac_arrest_bbw_deflection_iv_only"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, proteasome_inhibitor_flag, epoxyketone_covalent_irreversible,
    #                    beta5_thr1_morpholine_hemiketal, de_novo_20s_biogenesis_recovery_48_72hr,
    #                    cardiac_arrest_bbw_deflection, iv_only_route_gap, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_carfilzomib("868540-17-4", 0.00041, route="iv_30min"))
    print(r)
    # {'hd_category': 1, 'proteasome_inhibitor_flag': True,
    #  'epoxyketone_covalent_irreversible': True,
    #  'beta5_thr1_morpholine_hemiketal': True,
    #  'de_novo_20s_biogenesis_recovery_48_72hr': True,
    #  'cardiac_arrest_bbw_deflection': True,
    #  'iv_only_route_gap': True,
    #  'h340_h350_h361_absent': True}